Humacyte Inc reports results for the quarter ended December 31 - Earnings Summary

Humacyte

28/03/2025 13:30

Humacyte Inc HUMA.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -24 cents.  The mean expectation of seven analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -30 cents to -22 cents per share.

Reported revenue was zero​; analysts expected $214.29 thousand.

Humacyte Inc's reported EPS for the quarter was a loss of 16 cents​.

The company reported a quarterly loss of $20.94 million.

Humacyte Inc shares had fallen by 60.2% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Humacyte Inc is $10.00

This summary was machine generated from LSEG data March 28 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.25
-0.16
Beat
Sep. 30 2024
-0.25
-0.33
Missed
Jun. 30 2024
-0.24
-0.48
Missed
Mar. 31 2024
-0.22
-0.29
Missed